Bio Blue Bird's Acquisition

Bio Blue Bird was acquired by PharmaCyte Biotech on July 18, 2013.

Bio Blue Bird (BBB) owns exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment that has been used in two independent Phase II clinical trials which…

Articles about Bio Blue Bird's Acquisition: